Cesca Therapeutics Inc. is focused on the research, development and commercialization of autologous cell-based therapeutics for use in regenerative medicine. The Company is engaged in developing and manufacturing automated blood and bone marrow processing systems that enable the separation processing and preservation of cell and tissue therapy products. It focuses in three target markets to serve patients physicians and partners: cellular therapeutics, medical/diagnostic device development and commercialization, and cell manufacturing and banking. The Company focuses on three areas: critical limb ischemia (CLI), acute myocardial infarction (AMI) and bone marrow transplant (BMT). The Company offers SurgWerks and VXP System Platform, and CellWerks Platform. Its products include AutoXpress (AXP) System, MarrowXpress (MXP) System, BioArchive System and Res-Q 60 BMC. It also provides cell manufacturing and banking services.
